scholarly journals ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

2013 ◽  
Vol 6 (1) ◽  
pp. 25 ◽  
Author(s):  
Matthew J Schultz ◽  
Amanda F Swindall ◽  
John W Wright ◽  
Elizabeth S Sztul ◽  
Charles N Landen ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Ovarian Tumor ◽  
Cisplatin Resistance ◽  
St6gal I ◽  
Ovarian Tumor Cells

scholarly journals MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Meysam Moghbeli
Keyword(s):  
Ovarian Cancer ◽  
Tumor Cells ◽  
Treatment Option ◽  
Ovarian Tumor ◽  
Cisplatin Resistance ◽  
Present Review ◽  
Screening Methods ◽  
Non Invasive ◽  
Tumor Stages ◽  
Ovarian Tumor Cells

Abstract Background Ovarian cancer (OC) is one of the leading causes of cancer related deaths among women. Due to the asymptomatic tumor progression and lack of efficient screening methods, majority of OC patients are diagnosed in advanced tumor stages. A combination of surgical resection and platinum based-therapy is the common treatment option for advanced OC patients. However, tumor relapse is observed in about 70% of cases due to the treatment failure. Cisplatin is widely used as an efficient first-line treatment option for OC; however cisplatin resistance is observed in a noticeable ratio of cases. Regarding, the severe cisplatin side effects, it is required to clarify the molecular biology of cisplatin resistance to improve the clinical outcomes of OC patients. Cisplatin resistance in OC is associated with abnormal drug transportation, increased detoxification, abnormal apoptosis, and abnormal DNA repair ability. MicroRNAs (miRNAs) are critical factors involved in cell proliferation, apoptosis, and chemo resistance. MiRNAs as non-invasive and more stable factors compared with mRNAs, can be introduced as efficient markers of cisplatin response in OC patients. Main body In present review, we have summarized all of the miRNAs that have been associated with cisplatin resistance in OC. We also categorized the miRNAs based on their targets to clarify their probable molecular mechanisms during cisplatin resistance in ovarian tumor cells. Conclusions It was observed that miRNAs mainly exert their role in cisplatin response through regulation of apoptosis, signaling pathways, and transcription factors in OC cells. This review highlighted the miRNAs as important regulators of cisplatin response in ovarian tumor cells. Moreover, present review paves the way of suggesting a non-invasive panel of prediction markers for cisplatin response among OC patients.

SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells

2008 ◽  
Vol 111 (1) ◽  
pp. 125-131 ◽  
Author(s):  
Michelle M. Woo ◽  
Clara M. Salamanca ◽  
Jaime Symowicz ◽  
M. Sharon Stack ◽  
Dianne M. Miller ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Ovarian Tumor ◽  
Borderline Ovarian Tumor ◽  
Early Genes ◽  
Ovarian Tumor Cells

Immune evasion by melanoma and ovarian tumor cells through upregulation of the immunosuppressive molecule CD200

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 2545-2545
Author(s):  
A. Siva ◽  
H. Xin ◽  
F. Qin ◽  
A. Mickel ◽  
S. Faas ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Cells ◽  
Cell Lines ◽  
Ovarian Tumor ◽  
Cytokine Production ◽  
Ovarian Cancer Cell ◽  
Ovarian Adenocarcinoma ◽  
Ovarian Cancer Cell Lines ◽  
Th1 Cytokine ◽  
Ovarian Tumor Cells

2545 Background: Immune escape by tumors can occur by multiple mechanisms, each a significant barrier to immunotherapy. Upregulation of the immunosuppressive molecule CD200 on chronic lymphocytic leukemia cells inhibits Th1 cytokine production required for an effective cytotoxic T cell response. CD200 expression on human tumor cells in animal models prevents human lymphocytes from rejecting the tumor; treatment with an antagonistic anti-CD200 antibody restored lymphocyte-mediated tumor growth inhibition. This study evaluated CD200 expression on other cancers, and its effect on immune response. Methods: CD200 levels in ovarian adenocarcinoma and metastatic melanoma samples were evaluated by RT-QPCR and immunohistochemistry. Cell-surface CD200 on melanoma and ovarian cancer cell lines was assessed by flow cytometry. The effect of CD200 on cytokine production in mixed lymphocyte reactions (MLR) was assessed by adding the cells to cultures containing human monocyte-derived dendritic cells and allogeneic T cells. Th1 and Th2 cytokines in culture supernatants were detected by ELISA. Results: RT-QPCR showed CD200 expression levels upregulated in serous ovarian adenocarcinoma compared to normal samples. In malignant melanoma, CD200 expression in jejunum metastases was significantly higher than in normal samples, and 2 of 6 lung metastases showed CD200 upregulation. IHC showed strong, membrane-associated CD200 staining on malignant cells of two melanoma patients. Three ovarian cancer patients showed varying levels of CD200 tumor staining; all showed strong stromal staining. CD200 was highly expressed on the cell surface of SK-MEL-24 and SK-MEL-28 melanoma and OV-CAR-3 ovarian cancer cell lines and moderately expressed on the melanoma cell line SK-MEL-5. Addition of these cell lines to MLRs downregulated the production of Th1 cytokines; addition of CD200-negative cell lines did not. Inclusion of an antagonistic anti-CD200 antibody during the culture restored Th1 cytokine responses. Conclusion: Melanoma and ovarian tumor cells can upregulate CD200, thereby potentially suppressing anti-tumor immune responses. Therapy with an antagonistic anti-CD200 antibody may permit an effective cytotoxic immune response against the tumor cells. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document